These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23046397)

  • 1. Technosphere insulin effectively controls postprandial glycemia in patients with type 2 diabetes mellitus.
    Zisser H; Jovanovic L; Markova K; Petrucci R; Boss A; Richardson P; Mann A
    Diabetes Technol Ther; 2012 Nov; 14(11):997-1001. PubMed ID: 23046397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.
    Akturk HK; Snell-Bergeon JK; Rewers A; Klaff LJ; Bode BW; Peters AL; Bailey TS; Garg SK
    Diabetes Technol Ther; 2018 Oct; 20(10):639-647. PubMed ID: 30207748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9).
    Lane WS; Favaro E; Rathor N; Jang HC; Kjærsgaard MIS; Oviedo A; Rose L; Senior P; Sesti G; Soto Gonzalez A; Franek E
    Diabetes Care; 2020 Aug; 43(8):1710-1716. PubMed ID: 32209647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents.
    Rosenstock J; Bergenstal R; Defronzo RA; Hirsch IB; Klonoff D; Boss AH; Kramer D; Petrucci R; Yu W; Levy B;
    Diabetes Care; 2008 Nov; 31(11):2177-82. PubMed ID: 18678610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring.
    Matsuura K; Mori Y; Nakamura A; Yokoyama J; Utsunomiya K
    Diabetes Technol Ther; 2012 May; 14(5):423-9. PubMed ID: 22316114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes.
    Klonoff D; Bode B; Cohen N; Penn M; Geho WB; Muchmore DB
    Diabetes Care; 2019 Nov; 42(11):2154-2157. PubMed ID: 31551249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Afrezza on Glucose Dynamics During HCL Treatment.
    Galderisi A; Cohen N; Calhoun P; Kraemer K; Breton M; Weinzimer S; Cengiz E
    Diabetes Care; 2020 Sep; 43(9):2146-2152. PubMed ID: 32661108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Children and adolescents on intensive insulin therapy maintain postprandial glycaemic control without precise carbohydrate counting.
    Smart CE; Ross K; Edge JA; Collins CE; Colyvas K; King BR
    Diabet Med; 2009 Mar; 26(3):279-85. PubMed ID: 19317823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The additional dose of insulin for high-protein mixed meal provides better glycemic control in children with type 1 diabetes on insulin pumps: randomized cross-over study.
    Piechowiak K; Dżygało K; Szypowska A
    Pediatr Diabetes; 2017 Dec; 18(8):861-868. PubMed ID: 28117542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion.
    McVey E; Hirsch L; Sutter DE; Kapitza C; Dellweg S; Clair J; Rebrin K; Judge K; Pettis RJ
    J Diabetes Sci Technol; 2012 Jul; 6(4):743-54. PubMed ID: 22920798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
    Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
    Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience.
    Clarke WL; Anderson S; Breton M; Patek S; Kashmer L; Kovatchev B
    J Diabetes Sci Technol; 2009 Sep; 3(5):1031-8. PubMed ID: 20144416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus.
    Roach P; Arora V; Campaigne BN; Mattoo V; Rangwala S;
    Diabetes Obes Metab; 2003 Sep; 5(5):311-6. PubMed ID: 12940868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technosphere insulin technology.
    Richardson PC; Boss AH
    Diabetes Technol Ther; 2007 Jun; 9 Suppl 1():S65-72. PubMed ID: 17563306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
    Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH;
    Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.
    Malone JK; Woodworth JR; Arora V; Yang H; Campaigne BN; Hallé JP; Yale JF; Grossman LD
    Clin Ther; 2000 Feb; 22(2):222-30. PubMed ID: 10743981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
    Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.
    Jung JA; Kaku K; Kim JH; Kim JR; Ko JW; Lee SY; Huh W
    Adv Ther; 2013 Nov; 30(11):1018-29. PubMed ID: 24249434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter closed-loop insulin delivery study points to challenges for keeping blood glucose in a safe range by a control algorithm in adults and adolescents with type 1 diabetes from various sites.
    Zisser H; Renard E; Kovatchev B; Cobelli C; Avogaro A; Nimri R; Magni L; Buckingham BA; Chase HP; Doyle FJ; Lum J; Calhoun P; Kollman C; Dassau E; Farret A; Place J; Breton M; Anderson SM; Dalla Man C; Del Favero S; Bruttomesso D; Filippi A; Scotton R; Phillip M; Atlas E; Muller I; Miller S; Toffanin C; Raimondo DM; De Nicolao G; Beck RW;
    Diabetes Technol Ther; 2014 Oct; 16(10):613-22. PubMed ID: 25003311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.